I am always searching for the next Apple, but the probability of a company turning into another Apple is woefully low. However, from an investment perspective, finding another Apple simply means finding another stock that generates a several hundred percent return. There have been dozens of these situations in the past three years since the bear market bottom, and I have succeeded at riding several of them.
One thing I have never come across before is a company that calls itself the “Apple” of its industry in a letter to shareholders that was written to thwart a takeover bid. There had to be a first time.
Illumina (ILMN) recently wrote to its shareholders :
“Illumina is like the Apple of the genomics business. Tools made by the San Diego company are revered by genomics researchers around the world just like millions of consumers love their iPhones and iPads. And Illumina holds its dominant position at an enviable moment in history, as we’re heading into a scientific golden age when human genomes will be sequenced for $1,000 or less.” – Xconomy reporter Luke Timmerman, March 6, 2012
It is interesting to see companies other than Google(GOOG) trying to imitate Apple.
Illumina is locked in a bitter takeover battle with the Swiss giant Roche. In its attempt to stay independent, in addition to calling itself Apple, Illumina makes a persuasive case.
‘The rapid adoption of next-generation sequencing (“NGS”) in research and clinical settings places it among the most dynamic and fastest growing sectors of the life science tools industry, and Illumina …Read more at Forbes